



**Novartis India Limited**  
Registered Office:  
Inspire BKC  
7<sup>th</sup> Floor  
Bandra Kurla Complex  
Bandra (East)  
Mumbai – 400 051  
Maharashtra, India  
Tel +91 22 50243000  
Fax +91 22 50243010  
Email: india.investors@novartis.com  
CIN No. L24200MH1947PLC006104  
Website: www.novartis.in

October 18, 2023

To,  
The Secretary  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001

Scrip Code: 500 672

Dear Sir/ Madam,

**Sub.: Reconciliation of Share Capital Audit Report for the quarter ended September 30, 2023 under Regulation 76 of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 ('Regulations')**

Pursuant to Regulation 76 of the Regulations, please find enclosed herewith the Reconciliation of Share Capital Audit Report for the quarter ended September 30, 2023 obtained from Saraf & Associates, Company Secretaries.

This is for your information and records.

Thanking you,

Yours faithfully,

**For Novartis India Limited**

Malpani Nikhil Digitally signed by Malpani Nikhil  
DN: c=IN, o=Novartis, ou=People, ou=CR,  
serialNumber=3079258, cn=Malpani Nikhil  
Date: 2023.10.18 14:28:23 +05'30'

**Nikhil Malpani**  
**Company Secretary and Compliance Officer**

Encl.: as above

# SARAF & ASSOCIATES

## COMPANY SECRETARIES

www.sarafandassociates.com

423, Hind Rajasthan Building, 95, Dadasaheb Phalke Road, Dadar (C.Rly.), Mumbai - 400 014.

☎ (022) 2413 0371 / 2415 3887 ☎ +91 98203 20072 ✉ kamalax\_saraf@hotmail.com

### RECONCILIATION OF SHARE CAPITAL

1. For Quarter Ended : 30<sup>th</sup> September, 2023
2. ISIN : INE234A01025
3. Face Value : Rs.5/-
4. Name of the Company : Novartis India Limited
5. CIN : L24200MH1947PLC006104
6. Registered Office Address : Inspire BKC, 7th Floor, Bandra Kurla Complex,  
Bandra East, Mumbai City MH 400051.
7. Correspondence Address : Same as above
8. Telephone & Fax No. : (T)+91 22 50243000, (F) + 91 22 50243010
9. Email Address : india.investors@novartis.com
10. Name of the Stock Exchange : Bombay Stock Exchange (BSE)  
where the Company's securities  
are listed

|     |  | No. of Shares         | % of Total Issued Capital |
|-----|--|-----------------------|---------------------------|
| 11. | Issued Capital   | <b>24690797</b>       |                           |
| 12. | Listed Capital (Exchange wise)<br>BSE/NSE (As per Company Records)   | 24690797              | 100.00                    |
| 13. | Held in Dematerialised form in CDSL                                  | 2168028               | 8.78                      |
| 14. | Held in Dematerialised form in NSDL                                  | 22234574              | 90.05                     |
| 15. | Physical   | 288195                | 1.17                      |
| 16. | Total No. of Shares (13 + 14 + 15)                                   | <b>24690797</b>       | <b>100.00</b>             |
| 17. | Reasons for difference if any<br>Between (11&12) (11 & 16) (12 & 16) | <b>Not Applicable</b> |                           |

## RECONCILIATION OF SHARE CAPITAL AUDIT

18. Certifying the details of change in share capital during the quarter under consideration as per Table below:

| Particulars<br>*** | No of shares | Applied / Not Applied for Listing | Listed on Stock Exchange (Specify Name) | Whether Intimated to CDSL | Whether Intimated to NSDL | In Principle Appl. Pending for SE (Specify Names) |
|--------------------|--------------|-----------------------------------|---|---------------------------|---------------------------|---|
| NIL                |              |                                   |   |                           |                           |   |

\*\*\* Rights, Bonus, Preferential Issues, ESOP's, Amalgamation, Conversion, Buyback, Capital Reduction, Forfeiture, Any other (to Specify)

19. Register of Members is updated (Yes/No) : Yes

20. Reference of previous quarter with regards to excess dematerialized shares if any : Nil

21. Has the company resolved the matter mentioned in point no.20 above in the current quarter? if not, reason why? :N.A.

22. Mention the total no. of requests, if any, Confirmed after 21 days and the total No. of requests pending beyond 21 days with the Reasons for delay \* :

| Total No. of Demat Requests   | No of Requests | No of Shares | Reasons for delay |
|-------------------------------|----------------|--------------|-------------------|
| Confirmed after 21 days       | Nil            | Nil          | N.A.              |
| Pending for more than 21 days | Nil            | Nil          | N.A.              |

23. Name, Telephone & Fax no. of the Compliance Officer of the Company : Mr. Nikhil Malpani (A20869)  
Company Secretary and Compliance Officer  
Tel : +91 22 50243000  
Fax: +91 22 50243010

24. Name, Address, Tel, and Fax no. Regn. No. of the Auditor : K.G. SARAF  
SARAF & ASSOCIATES  
Practising Company Secretaries  
423,Hind Rajasthan Bldg.  
95, D.S.P. Road, Dadar (East),  
Mumbai – 400014.  
Tel.No.24130371/24153887  
Membership No : F1596 : CP No.642.

## RECONCILIATION OF SHARE CAPITAL AUDIT

25. Appointment of Common Agency for Share Registry Work : LINK INTIME INDIA PVT. LTD  
C-101, 247 Park,  
L.B.S. Marg, Vikhroli (W),  
Mumbai – 400083.

26. Any other details that the Auditor may like to provide (e.g. BIFR Company, delisting from SE, Company changed its name etc.) :

**Place : Mumbai**

**Date : 18/10/2023**

**UDIN : F001596E001356158**

**For SARAF & ASSOCIATES**

KAMALAX  
GANAPAYYA  
SARAF

Digitally signed by KAMALAX  
GANAPAYYA SARAF  
Date: 2023.10.18 13:48:40  
+05'30'

**K.G. SARAF**

**Practising Company Secretary**

**FCS: 1596 CP: 642**

**FRN. S1988MH004800**

**PR. 1003/2020**